{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=3%25+Sodium+Chloride&page=3",
    "query": {
      "intervention": "3% Sodium Chloride",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 2282,
    "total_pages": 229,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=3%25+Sodium+Chloride&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=3%25+Sodium+Chloride&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T18:30:51.849Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06695130",
      "title": "Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19 Immunization",
        "Influenza Immunization"
      ],
      "interventions": [
        {
          "name": "RIV (recombinant influenza vaccine)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rC19 (dose 1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RIV + rC19 (dose 1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RIV + rC19 (dose 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RIV + rC19 (dose 3)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "RIV + rC19 (dose 4)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (0.9% NaCl)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 980,
      "start_date": "2024-11-18",
      "completion_date": "2026-04-03",
      "has_results": false,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-07T18:30:51.849Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Cerritos, California • Vista, California + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        },
        {
          "city": "Melbourne",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06695130"
    },
    {
      "nct_id": "NCT04861077",
      "title": "Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "[18F]FMISO-PET with contrast-enhanced MRI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 75 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2027-06",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-10-07T18:30:51.849Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04861077"
    },
    {
      "nct_id": "NCT02138734",
      "title": "A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-muscle Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "BCG (50mg/instillation) + N-803 (400 μg/instillation)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BCG (50mg/instillation)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ImmunityBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 369,
      "start_date": "2014-07-21",
      "completion_date": "2039-03-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-10-07T18:30:51.849Z",
      "location_count": 72,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 60 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02138734"
    },
    {
      "nct_id": "NCT00646399",
      "title": "Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Staphylococcal Sepsis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pagibaximab 50 mg/mL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biosynexus Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "48 Hours",
        "sex": "ALL",
        "summary": "Up to 48 Hours"
      },
      "enrollment_count": 1579,
      "start_date": "2009-03",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2011-10-24",
      "last_synced_at": "2026-10-07T18:30:51.849Z",
      "location_count": 1,
      "location_summary": "Gaithersburg, Maryland",
      "locations": [
        {
          "city": "Gaithersburg",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00646399"
    },
    {
      "nct_id": "NCT00957905",
      "title": "Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Extragonadal Seminoma",
        "Recurrent Malignant Extragonadal Germ Cell Tumor",
        "Recurrent Malignant Extragonadal Non-Seminomatous Germ Cell Tumor",
        "Recurrent Malignant Testicular Germ Cell Tumor",
        "Recurrent Ovarian Germ Cell Tumor",
        "Stage III Testicular Cancer",
        "Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor",
        "Stage IV Extragonadal Seminoma",
        "Stage IV Ovarian Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "Alvocidib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin Calcium",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2009-06",
      "completion_date": "2014-08",
      "has_results": true,
      "last_update_posted_date": "2017-03-10",
      "last_synced_at": "2026-10-07T18:30:51.849Z",
      "location_count": 10,
      "location_summary": "Beverly Hills, California • Duarte, California • Los Angeles, California + 6 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00957905"
    },
    {
      "nct_id": "NCT00580619",
      "title": "Autonomic Nervous System and Chronic Fatigue Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Fatigue Syndrome",
        "Orthostatic Intolerance",
        "Postural Tachycardia Syndrome"
      ],
      "interventions": [
        {
          "name": "Autonomic Function Testing",
          "type": "OTHER"
        },
        {
          "name": "Saline infusions",
          "type": "OTHER"
        },
        {
          "name": "L-NMMA trimethaphan",
          "type": "DRUG"
        },
        {
          "name": "methyldopa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 170,
      "start_date": "2007-04",
      "completion_date": "2017-01",
      "has_results": false,
      "last_update_posted_date": "2017-01-18",
      "last_synced_at": "2026-10-07T18:30:51.849Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00580619"
    },
    {
      "nct_id": "NCT06305793",
      "title": "RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long COVID",
        "Long Coronavirus Disease 2019 (Covid19)",
        "Long Covid-19"
      ],
      "interventions": [
        {
          "name": "IVIG (intravenous immunoglobulin)",
          "type": "DRUG"
        },
        {
          "name": "IVIG Placebo",
          "type": "DRUG"
        },
        {
          "name": "Coordinated Care",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Kanecia Obie Zimmerman",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2024-05-08",
      "completion_date": "2026-06-22",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-07T18:30:51.849Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06305793"
    },
    {
      "nct_id": "NCT03524118",
      "title": "Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Tract Infection",
        "Respiratory Syncytial Virus"
      ],
      "interventions": [
        {
          "name": "Clesrovimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Weeks",
        "maximum_age": "8 Months",
        "sex": "ALL",
        "summary": "2 Weeks to 8 Months"
      },
      "enrollment_count": 183,
      "start_date": "2018-09-20",
      "completion_date": "2022-09-14",
      "has_results": true,
      "last_update_posted_date": "2025-01-14",
      "last_synced_at": "2026-10-07T18:30:51.849Z",
      "location_count": 17,
      "location_summary": "Aurora, Colorado • Homestead, Florida • Miami, Florida + 14 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Homestead",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Topeka",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03524118"
    },
    {
      "nct_id": "NCT04704336",
      "title": "Integration of Hypertension Management Into HIV Care in Nigeria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Human Immunodeficiency Virus",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Task-shifting strategy for HTN control (TASSH) protocol",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 830,
      "start_date": "2021-09-13",
      "completion_date": "2026-01-31",
      "has_results": true,
      "last_update_posted_date": "2026-06-24",
      "last_synced_at": "2026-10-07T18:30:51.849Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04704336"
    },
    {
      "nct_id": "NCT06059846",
      "title": "A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Tract Infection",
        "Acute Pyelonephritis"
      ],
      "interventions": [
        {
          "name": "TBP-PI-HBr",
          "type": "DRUG"
        },
        {
          "name": "Imipenem-cilastatin",
          "type": "DRUG"
        },
        {
          "name": "Dummy Infusion",
          "type": "DRUG"
        },
        {
          "name": "Dummy Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spero Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1690,
      "start_date": "2023-12-21",
      "completion_date": "2025-02-06",
      "has_results": true,
      "last_update_posted_date": "2026-03-10",
      "last_synced_at": "2026-10-07T18:30:51.849Z",
      "location_count": 2,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06059846"
    }
  ]
}